| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | IL3R; CD123; IL3RX; IL3RY; IL3RAY; hIL-3Ra |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthetic peptide of human IL3RA |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于IL3RA抗体的参考文献概览：
1. **"Targeting IL3RA in acute myeloid leukemia: preclinical and clinical evaluation of a novel therapeutic antibody"**
*作者：Smith A, et al. (2021)*
**摘要**：研究报道了一种新型抗IL3RA(CD123)单克隆抗体在急性髓系白血病(AML)中的疗效，通过体外和体内实验证明其可选择性杀伤白血病干细胞，并已进入I期临床试验。
2. **"IL3RA as a biomarker for plasmacytoid dendritic cells in autoimmune diseases"**
*作者：Zhang L, et al. (2019)*
**摘要**：文章揭示了IL3RA在浆细胞样树突状细胞(pDC)中的高表达特性，提出其作为自身免疫疾病(如红斑狼疮)中pDC激活的潜在生物标志物及治疗靶点。
3. **"A bispecific antibody targeting IL3RA and CD3 enhances antitumor immunity in hematologic malignancies"**
*作者：Brown K, et al. (2022)*
**摘要**：开发了一种双特异性抗体，同时靶向IL3RA和T细胞表面CD3分子，可引导T细胞特异性清除IL3RA高表达的血液肿瘤细胞，显著抑制小鼠模型中肿瘤生长。
注：以上文献信息为示例，实际引用需根据具体论文核实。如需全文链接或DOI可进一步补充检索。
The interleukin-3 receptor alpha (IL3RA, also known as CD123) is a transmembrane protein that serves as the primary ligand-binding subunit of the interleukin-3 receptor (IL-3R). It pairs with the common beta chain (βc) to form a functional receptor complex, enabling IL-3 signaling via JAK-STAT, MAPK, and PI3K pathways, which regulate cell proliferation, survival, and differentiation. IL3RA is predominantly expressed on hematopoietic cells, including plasmacytoid dendritic cells, basophils, and certain leukemic blasts, making it a biomarker for hematologic malignancies like acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).
IL3RA-targeting antibodies have gained attention as therapeutic and diagnostic tools. In research, anti-IL3RA antibodies are used to study IL-3 signaling dynamics, receptor distribution, and disease mechanisms. Clinically, monoclonal antibodies (e.g., tagraxofusp) and antibody-drug conjugates (ADCs) targeting CD123 exploit its overexpression on malignant cells for targeted therapy. Bispecific antibodies engaging T cells (e.g., CD123xCD3) are also under investigation to enhance antitumor immunity. However, challenges like on-target/off-tumor toxicity and variable receptor density in tumors necessitate careful optimization. Despite these hurdles, IL3RA remains a promising target for precision oncology, particularly in refractory hematologic cancers.
×
